| Therapeutic | Lampalizumab |
| Target | CFD |
| Heavy Chain | EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS |
| Light Chain | DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK |
| 100% seqID Fv Structure | 4d9q [Fvs: ED, HL], 4d9r [Fvs: ED, HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 4d9q [Fvs: ED, HL] |
| 100% seqID Structure | 4d9r [Fvs: ED, HL] |
Follow these links to our prediction tools:
| Format | Fab |
| Isotype | G1 |
| Highest Clinical Trial (June '19) | Phase-III |
| Estimated Status (June '19) | Discontinued |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2012 |
| INN Year Recommended | 2013 |
| Companies Involved | Tanox, Genentech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Dry age-related macular degeneration |
| Notes |
